“This disappointing decision is based on legal and factual errors we are confident will be reversed on appeal,” Joseph K. Belanoff, Corcept’s CEO, said in a statement.
January 03, 2024 at 06:43 PM
3 minute read
A Camden, New Jersey, federal judge ruled that Teva Pharmaceuticals USA Inc.’s application to make a generic version of a drug called Korlym did not infringe on patents on the drug that are held by Corcept Therapeutics.
The ruling allows Teva, an Israeli company whose U.S. headquarters is in Parsippany, New Jersey, to proceed with plans to sell its own version of Korlym.
Presented by BigVoodoo
New Jersey Law Journal honors lawyers leaving a mark on the legal community in New Jersey with their dedication to the profession.
The premier educational and networking event for employee benefits brokers and agents.
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania and Delaware.
Truly exceptional Bergen County New Jersey Law Firm is growing and seeks strong plaintiff's personal injury Attorney with 5-7 years plaintif...
Shipman is seeking an associate to join our Labor & Employment practice in our Hartford, New Haven, or Stamford office. Candidates shou...
Evergreen Trading is a media investment firm headquartered in NYC. We help brands achieve their goals by leveraging their unwanted assets to...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
Credit: jetcityimage/Adobe Stock
